 Danzi and colleagues published a second clinical trial comparing echocardiographic, angiographic and clinical outcomes in 100 patients with ST-segment elevation myocardial infarction STEMI who were treated with SHDB tirofiban versus abciximab7. There was slightly greater improvement in echocardiographic outcomes in patients treated with HDB tirofiban compared with abciximab. Angiographic and clinical outcomes were similar for the two groups. Again, while there was no incidence of major bleeding or severe thrombocytopenia reported for either treatment group, there were actually less episodes of minor bleeding in patients treated with SHDB tirofiban compared with abciximab 4 vs. 8; P 0.71. In short, this clinical experience demonstrated that SHDB tirofiban, administered at the time of PCI, was comparable to abciximab in treating STEMI patients undergoing PCI. 